Femasys

Update in progress

FEMY (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryMedical Instruments & Supplies

Femasys Inc. is a biomedical company that develops therapeutic and diagnostic solutions for women’s health in the United States and internationally. Its portfolio includes FemaSeed for intratubal insemination, FemVue for fallopian tube assessment via ultrasound, FemCerv for cervical cancer sampling, FemCath for selective fallopian tube evaluation, FemChec as a contrast-based fallopian tube diagnostic, and FemBloc, a non-surgical permanent birth-control option. Based in Suwanee, Georgia, since 2004.

Company score

Sentiment: 0.54; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.45; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.16; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.17; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.35; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive